Jacene, Heather A.
DiPiro, Pamela J.
Bellon, Jennifer
Hu, Jiani
Cheng, Su-Chun
Warren, Laura
Schlosnagle, Emily
Nakhlis, Faina
Rosenbluth, Jennifer M.
Yeh, Eren
Overmoyer, Beth
Article History
Received: 25 October 2019
Accepted: 7 April 2020
First Online: 21 April 2020
Compliance with ethical standards
:
: Heather Jacene has received honoraria from Janssen Pharmaceuticals, Bayer Healthcare; research support from Siemens Healthcare, Inc, GTx, Inc; and consulting from Advanced Accelerator Applications. Beth Overmoyer has received clinical trial support from Genentech, Incyte, GTx, and Eisai. All other authors have no declarations of interest.
: This was a retrospective study involving data from human participants. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Dana-Farber/Harvard Cancer Center Institutional Review Boards; DFCI 12-156) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: This was a retrospective study and the requirement for informed consent was waived by the Dana-Farber/Harvard Cancer Center Institutional Review Board (DFCI clinical trial numberĀ 12-156).